CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.
Products, services, technology
ClagalsiR is CALDRE’s first-in-class GalNAc-siRNA targeting Claudin-3 to restore bile flow and prevent fibrosis. Designed for patients with rare cholestatic liver diseases such as PSC, PBC, it offers a precision RNA approach to halt disease progression and prevent the need for liver transplantation.
Cooperation possibilities
CALDRE seeks partners in the oligonucleotide or liver disease field to advance its first-in-class GalNAc-siRNA platform restoring bile flow and preventing fibrosis. We welcome collaborations in co-development, licensing, or strategic alliances to drive RNA-based precision therapies forward.
- http://www.caldre.ch
- Send an email
- Felix Baier
Some insights
We aim to transform the life of patients with rare liver diseases by restoring liver function and preventing organ failure and disease symptoms. Our RNA therapies reduce patient and socio-economic burden while driving innovation, talent, and value creation within Switzerland’s biotech ecosystem.
We are proud that CALDRE grew from a breakthrough basic science discovery into a bold biotech venture. By translating our science based on a novel target from bench to bedside, we strive to make a lasting impact on patients while proving that visionary ideas can become real therapies.
Our team combines deep scientific, translational, and entrepreneurial expertise with strong execution in liver therapeutics. We aim to expand with experts in CMC, regulatory, and clinical development to accelerate ClagalsiR toward clinical and commercial success.
"My dad helps people with sick livers. He spends lots of time in meetings and says complicated words. I think he wants to make people healthy again."
We seek to connect with pharma and biotech companies focused on liver or oligonucleotide therapeutics, investors with strategic expertise in these fields, and experienced professionals who share our vision to bring RNA-based liver therapies to patients.
